Clinical Trial Update: PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) [Phase 2]

View source ↗

Summary

Phase 2 dose-escalation study of PF-04523655, with and without ranibizumab, in diabetic macular edema, with exploration in related retinal diseases. The trial s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetic Macular Edema
• Diabetic Retinopathy

Drugs mentioned

• PF-04523655
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Quark Pharmaceuticals | Conditions: Choroidal Neovascularization, Diabetic Retinopathy | Phase 2 | Status: COMPLETED